Home / Data / Corporate Press Release Ledger / 0001193125-26-324972 0001193125-26-324972 The Corporate Press Release Ledger tracks 8-K Regulation FD and Item 7.01 and 8.01 press-release filings with extracted exhibit titles, detected wire services and topic families, drawn from public SEC EDGAR data over a rolling window and refreshed daily. Every entry links the official filing; topics are derived labels, not issuer claims.
Records 4,303
Last changed 09/03/2026
Update schedule 11 13 * * * UTC
Coverage 07/20/2026–09/03/2026
Filing Date 07/30/2026
Issuer Evommune, Inc.
Press Release Title Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Release Topic clinical / regulatory
Wire Service Detected —
Is Reg Fd true Source U.S. Securities and Exchange Commission, EDGAR submissions, indexes, and filings · official record · retrieved 09/04/2026 · upstream last modified 07/30/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. Securities and Exchange Commission
Required notice Automated requests declare VUGA Enterprises LLC and an operator contact in the User-Agent header. What we add We compute Is Reg Fd, Has Press Release Exhibit, Release Topic, Release Topics All, Wire Service Detected, Release Length Words, Same Day Release Count, Issuer Sector, Public Significance Score using the documented compute method. · methodology